CICC: Upgrade Rongchang Biotech (09995.HK) target price to 77 Hong Kong dollars, rating upgraded to neutral.

Wisdom Financial APP learned that JPMorgan Chase released a research report, stating that it has lowered its product revenue forecast for Rongchang Biotech (09995, 688331.SH) in 2025 and 2026 to reflect the latest performance, while raising its authorized revenue forecast. With improving profit margins and reduced operating expenses, the bank expects the net loss for 2025 and 2026 to narrow, thus raising the H-share target price from 73 Hong Kong dollars to 77 Hong Kong dollars and upgrading the rating to neutral; the A-share target price has been raised from 86 yuan to 92 yuan, maintaining a "neutral" rating.